NCT02292433 - A Phase 1 Study In Japanese Subjects With Type 2 Diabetes Mellitus As Monotherapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

PF-04937319 high dose

tablets, 150 mg with breakfast plus 100 mg with lunch, 7 days

DRUG

PF-04937319 low dose

tablets, 50 mg with breakfast plus 50 mg with lunch, 7 days

DRUG

Placebo

tablets, breakfast plus lunch, 7 days

Trial Locations (1)

P-one Clinic, Keikokai Medical Corporation, Hachioji-shi